Key Points
- Mittie Doyle sold 25,492 Avalo Therapeutics shares on March 16 at an average price of $16.15, receiving $411,695.80 and reducing her stake by 87.56% to 3,622 shares.
- Shares opened at $14.68 (down about 4.6%), trading between a 12‑month low of $3.39 and high of $20.72, with a market cap of roughly $271.7 million and a negative P/E.
- Analysts show mixed but generally positive sentiment—MarketBeat reports a consensus rating of "Moderate Buy" with a $33 average target (individual targets range from $25 to $50), and institutions own about 87.06% of the stock.
Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) insider Mittie Doyle sold 25,492 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $16.15, for a total value of $411,695.80. Following the sale, the insider owned 3,622 shares of the company's stock, valued at approximately $58,495.30. The trade was a 87.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Avalo Therapeutics Stock Down 4.6%
Shares of NASDAQ AVTX opened at $14.68 on Thursday. Avalo Therapeutics, Inc. has a 12 month low of $3.39 and a 12 month high of $20.72. The company has a market cap of $271.73 million, a P/E ratio of -2.74 and a beta of 0.84. The business's 50 day moving average is $15.84 and its two-hundred day moving average is $15.65.
Analysts Set New Price Targets
A number of equities analysts recently issued reports on AVTX shares. Guggenheim assumed coverage on shares of Avalo Therapeutics in a research report on Monday, February 2nd. They set a "buy" rating and a $50.00 target price on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Avalo Therapeutics in a research report on Friday, January 9th. HC Wainwright reaffirmed a "buy" rating and set a $25.00 price objective on shares of Avalo Therapeutics in a research report on Thursday, January 15th. Finally, Mizuho upgraded shares of Avalo Therapeutics to a "strong-buy" rating in a research note on Thursday, December 18th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Avalo Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $33.00.
Get Our Latest Analysis on AVTX
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Velan Capital Investment Management LP increased its holdings in Avalo Therapeutics by 38.4% in the 2nd quarter. Velan Capital Investment Management LP now owns 154,972 shares of the company's stock valued at $773,000 after buying an additional 43,000 shares during the period. Patient Square Capital LP bought a new position in shares of Avalo Therapeutics during the 3rd quarter worth about $1,271,000. Cantor Fitzgerald L. P. bought a new stake in Avalo Therapeutics in the third quarter valued at about $1,083,000. Ally Bridge Group NY LLC acquired a new position in Avalo Therapeutics in the third quarter worth about $2,264,000. Finally, Aberdeen Group plc bought a new position in Avalo Therapeutics during the third quarter worth about $925,000. 87.06% of the stock is owned by institutional investors.
About Avalo Therapeutics
(
Get Free Report)
Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company's proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.
Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
